Related Experiment Videos
Update on newer neuromuscular blocking drugs
1Department of Anaesthesiology, Gentofte Hospital, University of Copenhagen, Denmark.
Annals of the Academy of Medicine, Singapore
|November 1, 1994
Summary
New non-depolarizing neuromuscular blocking drugs like mivacurium and rocuronium offer alternatives to succinylcholine. This review examines the pharmacokinetic and pharmacodynamic profiles of these advanced agents.
Area of Science:
- Anesthesiology
- Pharmacology
Background:
- The introduction of atracurium and vecuronium provided alternatives to succinylcholine for elective procedures.
- Recent advancements have expanded the range of non-depolarizing neuromuscular blocking drugs.
Purpose of the Study:
- To review the pharmacokinetic and pharmacodynamic profiles of newly available non-depolarizing neuromuscular blocking drugs.
- To provide an overview of short-acting, intermediate-acting, and long-acting neuromuscular blocking agents.
Main Methods:
- Literature review of pharmacokinetic and pharmacodynamic data.
- Analysis of recently introduced neuromuscular blocking drugs.
Main Results:
- Four new drugs are now available: mivacurium (short-acting), rocuronium (intermediate-acting), doxacurium (long-acting), and pipecuronium (long-acting).
- These agents offer varied durations of action and clinical profiles.
Conclusions:
- The availability of these new neuromuscular blocking drugs enhances anesthetic options.
- Understanding their pharmacokinetic and pharmacodynamic properties is crucial for clinical application.